Effectiveness of influenza and pneumococcal polysaccharide vaccines against influenza-related outcomes including pneumonia and acute exacerbation of cardiopulmonary diseases: Analysis by dominant viral subtype and vaccine matching

Joon-Young Song, Ji Yun Noh, Jin Soo Lee, Seong Heon Wie, Young Keun Kim, Jacob Lee, Hye Won Jeong, Shin Woo Kim, Sun Hee Lee, Kyung Hwa Park, Wonseok Choi, Hee-Jin Cheong, Woo Joo Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Influenza and pneumonia are leading causes of morbidity and mortality among the elderly. Although vaccination is a main strategy to prevent these infectious diseases, concerns remain with respect to vaccine effectiveness. Methods During three influenza seasons (2014–2015, 2015–2016 and 2016–2017), we evaluated the effectiveness of the influenza and pneumococcal vaccines against pneumonia and acute exacerbation of cardiopulmonary diseases among the elderly aged 65 years with influenza-like illness (ILI). Demographic and clinical data were collected prospectively. Results Among 2,119 enrolled cases, 1,302 (61.4%) and 871 (41.1%) received the influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (PPV23), respectively. During an A/H3N2-dominant season with poor influenza vaccine effectiveness (2014–2015 season), neither the influenza vaccine nor PPV23 showed significant effectiveness against pneumonia or acute exacerbation of cardiopulmonary diseases. During seasons with good influenza vaccine effectiveness (2015–2016 and 2016–2017 seasons), the influenza vaccine was effective in preventing pneumonia, but PPV23 was not. In particular, the influenza vaccine was effective in preventing acute exacerbation of heart diseases (75.0%) during the A/ H1N1-dominant 2015–2016 season. Conclusion The influenza vaccine was effective in preventing pneumonia only during vaccine-matched seasons with good effectiveness against circulating influenza viruses. In addition, the influenza vaccine was cardio-protective during a vaccine-matched A/H1N1-dominant season.

Original languageEnglish
Article numbere0207918
JournalPLoS One
Volume13
Issue number12
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Viral Vaccines
Pneumococcal Vaccines
Influenza Vaccines
influenza
Human Influenza
pneumonia
Disease Progression
Pneumonia
polysaccharides
Vaccines
vaccines
Orthomyxoviridae
Viruses
Communicable Diseases
Heart Diseases
Vaccination
heart diseases
Demography
Morbidity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Effectiveness of influenza and pneumococcal polysaccharide vaccines against influenza-related outcomes including pneumonia and acute exacerbation of cardiopulmonary diseases : Analysis by dominant viral subtype and vaccine matching. / Song, Joon-Young; Noh, Ji Yun; Lee, Jin Soo; Wie, Seong Heon; Kim, Young Keun; Lee, Jacob; Jeong, Hye Won; Kim, Shin Woo; Lee, Sun Hee; Park, Kyung Hwa; Choi, Wonseok; Cheong, Hee-Jin; Kim, Woo Joo.

In: PLoS One, Vol. 13, No. 12, e0207918, 01.12.2018.

Research output: Contribution to journalArticle

@article{9ecb9a45313f44478fd31b4a46cb2368,
title = "Effectiveness of influenza and pneumococcal polysaccharide vaccines against influenza-related outcomes including pneumonia and acute exacerbation of cardiopulmonary diseases: Analysis by dominant viral subtype and vaccine matching",
abstract = "Background Influenza and pneumonia are leading causes of morbidity and mortality among the elderly. Although vaccination is a main strategy to prevent these infectious diseases, concerns remain with respect to vaccine effectiveness. Methods During three influenza seasons (2014–2015, 2015–2016 and 2016–2017), we evaluated the effectiveness of the influenza and pneumococcal vaccines against pneumonia and acute exacerbation of cardiopulmonary diseases among the elderly aged 65 years with influenza-like illness (ILI). Demographic and clinical data were collected prospectively. Results Among 2,119 enrolled cases, 1,302 (61.4{\%}) and 871 (41.1{\%}) received the influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (PPV23), respectively. During an A/H3N2-dominant season with poor influenza vaccine effectiveness (2014–2015 season), neither the influenza vaccine nor PPV23 showed significant effectiveness against pneumonia or acute exacerbation of cardiopulmonary diseases. During seasons with good influenza vaccine effectiveness (2015–2016 and 2016–2017 seasons), the influenza vaccine was effective in preventing pneumonia, but PPV23 was not. In particular, the influenza vaccine was effective in preventing acute exacerbation of heart diseases (75.0{\%}) during the A/ H1N1-dominant 2015–2016 season. Conclusion The influenza vaccine was effective in preventing pneumonia only during vaccine-matched seasons with good effectiveness against circulating influenza viruses. In addition, the influenza vaccine was cardio-protective during a vaccine-matched A/H1N1-dominant season.",
author = "Joon-Young Song and Noh, {Ji Yun} and Lee, {Jin Soo} and Wie, {Seong Heon} and Kim, {Young Keun} and Jacob Lee and Jeong, {Hye Won} and Kim, {Shin Woo} and Lee, {Sun Hee} and Park, {Kyung Hwa} and Wonseok Choi and Hee-Jin Cheong and Kim, {Woo Joo}",
year = "2018",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0207918",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Effectiveness of influenza and pneumococcal polysaccharide vaccines against influenza-related outcomes including pneumonia and acute exacerbation of cardiopulmonary diseases

T2 - Analysis by dominant viral subtype and vaccine matching

AU - Song, Joon-Young

AU - Noh, Ji Yun

AU - Lee, Jin Soo

AU - Wie, Seong Heon

AU - Kim, Young Keun

AU - Lee, Jacob

AU - Jeong, Hye Won

AU - Kim, Shin Woo

AU - Lee, Sun Hee

AU - Park, Kyung Hwa

AU - Choi, Wonseok

AU - Cheong, Hee-Jin

AU - Kim, Woo Joo

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background Influenza and pneumonia are leading causes of morbidity and mortality among the elderly. Although vaccination is a main strategy to prevent these infectious diseases, concerns remain with respect to vaccine effectiveness. Methods During three influenza seasons (2014–2015, 2015–2016 and 2016–2017), we evaluated the effectiveness of the influenza and pneumococcal vaccines against pneumonia and acute exacerbation of cardiopulmonary diseases among the elderly aged 65 years with influenza-like illness (ILI). Demographic and clinical data were collected prospectively. Results Among 2,119 enrolled cases, 1,302 (61.4%) and 871 (41.1%) received the influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (PPV23), respectively. During an A/H3N2-dominant season with poor influenza vaccine effectiveness (2014–2015 season), neither the influenza vaccine nor PPV23 showed significant effectiveness against pneumonia or acute exacerbation of cardiopulmonary diseases. During seasons with good influenza vaccine effectiveness (2015–2016 and 2016–2017 seasons), the influenza vaccine was effective in preventing pneumonia, but PPV23 was not. In particular, the influenza vaccine was effective in preventing acute exacerbation of heart diseases (75.0%) during the A/ H1N1-dominant 2015–2016 season. Conclusion The influenza vaccine was effective in preventing pneumonia only during vaccine-matched seasons with good effectiveness against circulating influenza viruses. In addition, the influenza vaccine was cardio-protective during a vaccine-matched A/H1N1-dominant season.

AB - Background Influenza and pneumonia are leading causes of morbidity and mortality among the elderly. Although vaccination is a main strategy to prevent these infectious diseases, concerns remain with respect to vaccine effectiveness. Methods During three influenza seasons (2014–2015, 2015–2016 and 2016–2017), we evaluated the effectiveness of the influenza and pneumococcal vaccines against pneumonia and acute exacerbation of cardiopulmonary diseases among the elderly aged 65 years with influenza-like illness (ILI). Demographic and clinical data were collected prospectively. Results Among 2,119 enrolled cases, 1,302 (61.4%) and 871 (41.1%) received the influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (PPV23), respectively. During an A/H3N2-dominant season with poor influenza vaccine effectiveness (2014–2015 season), neither the influenza vaccine nor PPV23 showed significant effectiveness against pneumonia or acute exacerbation of cardiopulmonary diseases. During seasons with good influenza vaccine effectiveness (2015–2016 and 2016–2017 seasons), the influenza vaccine was effective in preventing pneumonia, but PPV23 was not. In particular, the influenza vaccine was effective in preventing acute exacerbation of heart diseases (75.0%) during the A/ H1N1-dominant 2015–2016 season. Conclusion The influenza vaccine was effective in preventing pneumonia only during vaccine-matched seasons with good effectiveness against circulating influenza viruses. In addition, the influenza vaccine was cardio-protective during a vaccine-matched A/H1N1-dominant season.

UR - http://www.scopus.com/inward/record.url?scp=85057739685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057739685&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0207918

DO - 10.1371/journal.pone.0207918

M3 - Article

C2 - 30521553

AN - SCOPUS:85057739685

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0207918

ER -